Marjorie Taylor Greene Invests in Tech, Energy, and Biotech Stocks

Marjorie Taylor Greene, the US House Representative for Georgia’s 14th congressional district, has garnered significant wealth through her stock trading activities. Data from Quiver Quantitative estimates her personal net worth to be around $22.3 million. Greene’s recent stock investments have attracted attention, especially after making substantial profits during the tariff-induced market downturn.

She maintains a diverse investment portfolio that includes stocks in various sectors such as technology, financials, logistics, utility, and consumer discretionary. Recent reports indicate that Greene purchased shares in six companies on 6th June, focusing primarily on technology and energy stocks. One notable acquisition was shares in Gilead Sciences (NASDAQ:GILD), a biotech firm that received FDA approval for its groundbreaking HIV-prevention drug called Yeztugo.

Gilead Sciences announced on 18th June that Yeztugo had become the first FDA-approved HIV prevention option to offer six months of protection against the disease. Clinical trials showed nearly 100% efficacy in preventing HIV transmission among participants using the injectable capsid inhibitor. Daniel O’Day, Chairman and CEO of Gilead Sciences, hailed the drug as a significant milestone in the fight against HIV, emphasizing its potential to transform HIV prevention methods.

The FDA approval of Yeztugo has positioned Gilead Sciences for future growth, as the company prepares to make the drug accessible in the US and globally. Greene’s investment decisions also reflected her interest in technology and energy sectors, with purchases in companies like Adobe, Netflix, Snowflake, ServiceNow, and NextEra Energy. These tech firms are actively pursuing Generative AI applications to expand their customer base and cater to enterprise clients.

NextEra Energy, in particular, stands out for its consistent performance, benefiting from increasing electricity demands and delivering strong earnings growth. The company’s commitment to raising dividends annually through 2026 further enhances its appeal to investors. Despite public scrutiny and concerns about potential insider trading, US Congress members like Greene and Nancy Pelosi continue to engage in stock trading activities.

It is worth noting that the information presented in this article is for informational purposes only and should not be considered as investment advice. Readers are encouraged to conduct their research or seek advice from financial professionals before making investment decisions. As with any investment, risks are involved, and past performance may not indicate future returns.